

Reference number(s)
3078-H

SPECIALTY QUANTITY LIMIT PROGRAM

VYND AQEL (tafamidis meglumine) VYNDAMAX (tafamidis)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the FDA-approved indication fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Vyndaqel (tafamidis meglumine) 20 mg capsules	120 per 30 days	80 mg orally once daily
Vyndamax (tafamidis) 61 mg capsules	30 per 30 days	61 mg orally once daily

REFERENCES

1. Vyndaqel and Vydamax [package insert]. New York, NY: Pfizer Labs.; May 2019.